Trial Profile
Phase II Trial of Sorafenib for Patients With Metastatic or Recurrent Esophageal and Gastroesophageal Junction Cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer; Squamous cell cancer
- Focus Therapeutic Use
- 07 Aug 2018 Status changed from active, no longer recruiting to completed.
- 04 Jun 2018 Planned End Date changed from 1 Jun 2018 to 1 Jun 2019.
- 04 Jun 2018 Planned primary completion date changed from 1 Jun 2018 to 1 Jun 2019.